NSGCT
MCID: NNS011
MIFTS: 32

Nonseminomatous Germ Cell Tumor (NSGCT)

Categories: Rare diseases

Aliases & Classifications for Nonseminomatous Germ Cell Tumor

MalaCards integrated aliases for Nonseminomatous Germ Cell Tumor:

Name: Nonseminomatous Germ Cell Tumor 20 70
Non-Seminomatous Germ-Cell Tumors 20
Germ Cell Tumor, Nonseminomatous 6
Nsgct 20

Classifications:



External Ids:

UMLS 70 C1266158

Summaries for Nonseminomatous Germ Cell Tumor

GARD : 20 Nonseminomatous germ cell tumors are cancerous tumors commonly found in the pineal gland in the brain, in the mediastinum, or in the abdomen. They originate from cells that were meant to form sex cells (i.e., sperm or eggs). They are often large and have a tendency to spread more quickly than the other type of germ cell tumor (i.e., seminoma type). Possible early signs of this cancer include chest pain and breathing problems.

MalaCards based summary : Nonseminomatous Germ Cell Tumor, also known as non-seminomatous germ-cell tumors, is related to testicular germ cell tumor and teratoma. An important gene associated with Nonseminomatous Germ Cell Tumor is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are MAPK Pathway and Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors. The drugs Cisplatin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include testis, lymph node and pineal, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Nonseminomatous Germ Cell Tumor

Diseases related to Nonseminomatous Germ Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 testicular germ cell tumor 32.1 BRAF AFP
2 teratoma 31.0 CGB7 CGB5 AFP
3 endodermal sinus tumor 30.7 CGB5 AFP
4 malignant teratoma 30.6 CGB5 AFP
5 mature teratoma 30.5 ERBB2 BRAF AFP
6 trophoblastic neoplasm 30.4 CGB5 AFP
7 extragonadal germ cell cancer 30.4 CGB5 AFP
8 gonadal germ cell tumor 30.3 CGB5 AFP
9 choriocarcinoma 30.2 CGB7 CGB5
10 seminoma 30.1 CGB7 CGB5 AFP
11 placental site trophoblastic tumor 29.9 ERBB2 CGB5
12 gynecomastia 29.9 ERBB2 CGB5
13 extragonadal nonseminomatous germ cell tumor 11.5
14 germ cells tumors 11.2
15 testicular cancer 10.7
16 embryonal carcinoma 10.6
17 germ cell cancer 10.6
18 testicular germ cell cancer 10.5
19 growing teratoma syndrome 10.5
20 testicular yolk sac tumor 10.5
21 teratocarcinoma 10.4
22 mixed germ cell tumor 10.4
23 lymphocele 10.3
24 mucositis 10.2
25 hypogonadotropic hypogonadism 10.2
26 respiratory failure 10.2
27 adult respiratory distress syndrome 10.2
28 pancreatic adenocarcinoma 10.2
29 spermatocytoma 10.2
30 testicular spermatocytic seminoma 10.2
31 hyperthyroidism 10.2
32 renal cell carcinoma, nonpapillary 10.1
33 sarcoidosis 1 10.1
34 renal hypodysplasia/aplasia 1 10.1
35 ascites, chylous 10.1
36 chondrosarcoma 10.1
37 leukemia, acute myeloid 10.1
38 sarcoidosis 3 10.1
39 deficiency anemia 10.1
40 mastitis 10.1
41 hemopericardium 10.1
42 infant gynecomastia 10.1
43 pericardial effusion 10.1
44 thrombocytopenia 10.1
45 central nervous system disease 10.1
46 urinary tract obstruction 10.1
47 infertility 10.1
48 hemolytic anemia 10.1
49 severe combined immunodeficiency 10.1
50 nervous system disease 10.1

Graphical network of the top 20 diseases related to Nonseminomatous Germ Cell Tumor:



Diseases related to Nonseminomatous Germ Cell Tumor

Symptoms & Phenotypes for Nonseminomatous Germ Cell Tumor

GenomeRNAi Phenotypes related to Nonseminomatous Germ Cell Tumor according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.47 CGB5 CGB7
2 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.47 BRAF
3 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.47 ERBB2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.47 ERBB2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.47 ERBB2
6 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.47 CGB5 CGB7 ERBB2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.47 BRAF
8 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.47 ERBB2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.47 ERBB2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.47 ERBB2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.47 ERBB2

Drugs & Therapeutics for Nonseminomatous Germ Cell Tumor

Drugs for Nonseminomatous Germ Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
2
Ifosfamide Approved Phase 3 3778-73-2 3690
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
5
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
6
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
7
Isophosphamide mustard Phase 3 100427
8 Alkylating Agents Phase 3
9 Etoposide phosphate Phase 3
10 Antimitotic Agents Phase 3
11 Albumin-Bound Paclitaxel Phase 3
12 Tubulin Modulators Phase 3
13 Antibiotics, Antitubercular Phase 3
14 Anti-Bacterial Agents Phase 3
15
Gemcitabine Approved Phase 2 95058-81-4 60750
16
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
17 Anti-Infective Agents Phase 2
18 Immunosuppressive Agents Phase 2
19 Antiviral Agents Phase 2
20 Antimetabolites Phase 2
21 Immunologic Factors Phase 2
22 Fluorodeoxyglucose F18
23 Radiopharmaceuticals

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Single Group Trial Evaluating One Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Tumours of the Testis (NSGCTT) Active, not recruiting NCT01726374 Phase 3 BEP(500)
2 A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Active, not recruiting NCT00104676 Phase 3 cisplatin;etoposide;ifosfamide;oxaliplatin;paclitaxel
3 A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors Unknown status NCT02115165 Phase 2 Cabazitaxel
4 A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis Unknown status NCT00127049 Phase 2 gemcitabine, ifosfamide, cisplatin, G-CSF
5 A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy Completed NCT02317393 Phase 2
6 A Treatment Strategy of the Use of 1st Line Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Based on Tumor Marker Decline: A Phase II Trial of Paclitaxel, Ifosfamid and Cisplatin Regimen. Completed NCT02414685 Phase 2 Paclitaxel;Ifosfamide;Cisplatin
7 Assessment of the Utility of CT Follow Up in the Long Term Follow Up of Patients With Metastatic Non Seminomatous Germ Cell Tumour (NSGCT) Unknown status NCT00553371
8 A Study Of 18 FDG PET In The Prediction Of Relapse In Patients With A Clinical Stage I Non-Seminomatous Germ Cell Tumor Completed NCT00045045
9 Correlation of Histopathology, Immunohistochemistry and Quantitative Radiology With Outcome in Early Stage Nonseminomatous Germ Cell Tumor Completed NCT00003800

Search NIH Clinical Center for Nonseminomatous Germ Cell Tumor

Genetic Tests for Nonseminomatous Germ Cell Tumor

Anatomical Context for Nonseminomatous Germ Cell Tumor

MalaCards organs/tissues related to Nonseminomatous Germ Cell Tumor:

40
Testis, Lymph Node, Pineal, Ovary, Bone Marrow, Testes, Thyroid

Publications for Nonseminomatous Germ Cell Tumor

Articles related to Nonseminomatous Germ Cell Tumor:

(show top 50) (show all 905)
# Title Authors PMID Year
1
Codon-specific translation reprogramming promotes resistance to targeted therapy. 6
29925953 2018
2
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. 6
28854169 2017
3
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. 6
25079330 2014
4
Copper is required for oncogenic BRAF signalling and tumorigenesis. 6
24717435 2014
5
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 6
24670642 2014
6
Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. 6
24512911 2014
7
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. 6
23685455 2013
8
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. 6
23302800 2013
9
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. 6
22281684 2012
10
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). 6
22113612 2011
11
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 6
21107320 2010
12
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. 6
21107323 2010
13
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. 6
20823850 2010
14
Inhibition of mutated, activated BRAF in metastatic melanoma. 6
20818844 2010
15
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. 6
18398503 2008
16
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. 6
17785355 2007
17
BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. 6
17488796 2007
18
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. 6
17374713 2007
19
Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. 6
16772349 2006
20
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. 6
16174717 2005
21
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. 6
16015629 2005
22
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. 6
15998781 2005
23
High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. 6
16187918 2005
24
Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. 6
15687339 2005
25
Mutations of BRAF and RAS are rare events in germ cell tumours. 6
15386408 2005
26
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. 6
15342696 2004
27
Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. 6
15356022 2004
28
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. 6
15181070 2004
29
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. 6
15126572 2004
30
BRAF T1796A transversion mutation in various thyroid neoplasms. 6
15001635 2004
31
Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. 6
14513361 2003
32
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. 6
14602780 2003
33
Exclusion of BRAFV599E as a melanoma susceptibility mutation. 6
12794760 2003
34
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 6
12960123 2003
35
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. 6
12670889 2003
36
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. 6
12644542 2003
37
Absence of exon 15 BRAF germline mutations in familial melanoma. 6
12619120 2003
38
High frequency of BRAF mutations in nevi. 6
12447372 2003
39
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. 6
12198537 2002
40
Mutations of the BRAF gene in human cancer. 6
12068308 2002
41
Pathological predictors of metastatic disease in testicular non-seminomatous germ cell tumors: which tumor-node-metastasis staging system? 61
33319858 2021
42
Pure testicular choriocarcinoma Cannonball metastases as a presenting imaging feature: A case report and a review of literature. 61
33613805 2021
43
[Diagnostic value of diffusion-weighted imaging and conventional magnetic resonance imaging in testicular tumor]. 61
33685049 2021
44
Commentary: Predicting intrathoracic pathologic concordance in patients with metastatic nonseminomatous germ cell tumor is clearly unclear. 61
33451849 2021
45
Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest. 61
33478834 2021
46
Racial and socioeconomic disparities in retroperitoneal lymph node dissection and survival in nonseminomatous germ cell tumor: A population-based study. 61
33423934 2021
47
Primary mediastinal germ cell tumors - A retrospective analysis of >30 years of experience in a single institution. 61
33502089 2021
48
Unilateral or Bilateral Retroperitoneal Lymph Node Dissection in Nonseminoma Patients with Postchemotherapy Residual Tumour? Results from RETROP, a Population-based Mapping Study by the Swedish Norwegian Testicular Cancer Group. 61
33750683 2021
49
Could Aberrant Migration Explain Metachronous Germ Cell Tumors? 61
33017201 2021
50
Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer. 61
33119475 2021

Variations for Nonseminomatous Germ Cell Tumor

ClinVar genetic disease variations for Nonseminomatous Germ Cell Tumor:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BRAF NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu) SNV Pathogenic 13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336

Expression for Nonseminomatous Germ Cell Tumor

Search GEO for disease gene expression data for Nonseminomatous Germ Cell Tumor.

Pathways for Nonseminomatous Germ Cell Tumor

GO Terms for Nonseminomatous Germ Cell Tumor

Biological processes related to Nonseminomatous Germ Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.46 ERBB2 CGB7 CGB5 BRAF
2 peptidyl-tyrosine phosphorylation GO:0018108 9.26 ERBB2 BRAF
3 hormone-mediated signaling pathway GO:0009755 8.96 CGB7 CGB5
4 female gamete generation GO:0007292 8.62 CGB7 CGB5

Molecular functions related to Nonseminomatous Germ Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 8.96 ERBB2 BRAF
2 hormone activity GO:0005179 8.62 CGB7 CGB5

Sources for Nonseminomatous Germ Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....